Cases & Deals

Share

GE Healthcare acquires Rapidscan

January 2017

Client(s) General Electric Company

Jones Day advised GE Healthcare in connection with its acquisition of Rapidscan Pharma Solutions, Inc., which is a single product pharmaceutical company with the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside of North America.  Rapiscan® is a European Medicines Agency (EMA) approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.